Key Highlights
- Federal regulators confirmed 2027 Medicare Advantage payment policies with a net average 2.48% increase — representing more than $13 billion in sector-wide funding
- Shares of CVS climbed as much as 5.20% during Tuesday’s session, with Aetna positioned to benefit directly from the rate adjustment
- The 2024 risk-adjustment model will remain in effect for 2027, while CMS imposed stricter standards on unlinked chart review diagnoses
- Cantor Fitzgerald maintained its Overweight rating with a $95 target, pointing to Medicare Advantage margin improvement as a catalyst
- First-quarter 2026 earnings are scheduled for May 6, with Wall Street expecting $2.23 per share and $94.86 billion in revenue
CVS Health experienced a strong rally Tuesday following a Medicare Advantage policy announcement that lifted managed-care stocks across the board.
The Centers for Medicare & Medicaid Services released its final 2027 Medicare Advantage and Part D payment policies, announcing a net average increase of 2.48% — equivalent to over $13 billion in additional sector funding for calendar year 2027.
For CVS, the implications are significant. The company operates substantial Medicare Advantage operations through Aetna, complementing its pharmacy benefit management and retail pharmacy divisions.
Investors responded favorably to the announcement. CVS shares advanced as much as 5.20% during morning trading Tuesday.
Regulatory Details Include Tighter Coding Standards
The policy update came with nuances. CMS announced it will retain the 2024 risk-adjustment model for 2027, while implementing new restrictions that exclude diagnoses from unlinked chart reviews in most risk-score calculations.
These stricter standards could create challenges for insurers relying heavily on coding-driven reimbursement approaches. For CVS, operating across multiple healthcare segments, market participants appeared to prioritize the funding expansion over the technical adjustments.
The company has also seen improvement in its Stars ratings profile. Bonus-eligible Stars scores fell dramatically from 85% in 2022 to 21% in 2023 — a decline that pressured Medicare Advantage profitability during that stretch.
Cantor Fitzgerald, which reaffirmed its Overweight rating with a $95 price target Monday, noted that the Medicare Advantage division has additional runway to reach 3% margins, while projecting that 2026 individual Medicare Advantage margins have turned slightly profitable.
Shares traded at $73.28 ahead of Tuesday’s rally, a valuation that Cantor and peer firms consider attractive relative to intrinsic value.
Wall Street Maintains Positive Outlook Ahead of Earnings
Analyst sentiment toward CVS remains broadly supportive. The stock holds a consensus Buy rating with an average price target of $92.79.
Recent analyst activity includes Bernstein elevating the stock to Outperform with a $94 target in March, Piper Sandler maintaining Overweight while adjusting its target to $99, and Argus Research keeping its Buy rating with a $90 objective.
Leerink Partners also rates the stock Outperform with a $98 target, a perspective influenced partly by the recent FTC consent agreement involving Caremark and Zinc, which the firm viewed as reducing regulatory overhang.
On the strategic front, CVS recently entered into an asset purchase agreement with GenieRx Holdings, designating GenieRx as the stalking horse bidder for Omnicare’s court-supervised sale proceedings.
The company also added John E. Gallina, former CFO of Elevance Health, to its board of directors and audit committee.
Looking ahead: CVS will release Q1 2026 results on May 6. Consensus estimates call for EPS of $2.23 and revenue of $94.86 billion.
